Tirzepatide improves cholesterol and fat levels in the blood more than semaglutide, likely because it works on two hormones instead of one.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Establish causal superiority of tirzepatide over semaglutide for lipid and adiponectin outcomes.
A double-blind RCT of 1,500 adults with type 2 diabetes, randomized to tirzepatide 15 mg/week vs semaglutide 2.4 mg/week for 52 weeks, with change in triglycerides and adiponectin as co-primary endpoints, using central lab assays.
Quantify the average difference in lipid and adiponectin changes between dual and mono agonists.
A systematic review and meta-analysis of all head-to-head trials comparing tirzepatide to GLP-1RAs, extracting mean changes in triglycerides, HDL, LDL, and adiponectin with standard deviations.
Assess real-world lipid and adiponectin responses to these agents.
A prospective cohort of 6,000 patients with type 2 diabetes starting tirzepatide or semaglutide, with lipid panels and adiponectin measured at baseline and 1 year via standardized assays.
Estimate average lipid levels among users of each drug.
A cross-sectional study of 8,000 patients on tirzepatide or semaglutide, extracting latest lipid panel and adiponectin from EHRs, adjusting for age, sex, and statin use.
Interpret lipid and adiponectin findings in clinical context.
A narrative review discussing mechanisms of lipid modulation by incretins, summarizing trial data on tirzepatide vs semaglutide.